Company Announcement

• Genmab increases its share capital by nominally DKK 5,400,000 as a result of a private placement to Johnson & Johnson Development Corporation in connection with the daratumumab license agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical companies of Johnson & Johnson

Copenhagen, Denmark; October 16, 2012 – Genmab A/S (OMX: GEN) announces completion of the private placement of 5,400,000 new shares of DKK 1 nominal value each in Genmab A/S at a subscription price of DKK 88 per new share to Johnson & Johnson Development Corporation, raising gross proceeds to Genmab of DKK 475,200,000.

The private placement, which is made in connection with the global license and development agreement for daratumumab (HuMax®-CD38) between Genmab and Janssen Biotech, Inc., one of the Janssen Pharmaceutical companies of Johnson & Johnson, was originally announced on August 30, 2012 (Company Announcements 20, 21 and 22).

Genmab's current share capital amounts to DKK 50,307,142 after registration of the capital increase with the Danish Business Authority. Genmab's new articles of association will be published separately and are available at Genmab's website, www.genmab.com.

It is expected that the new shares will be admitted to trading and official listing on NASDAQ OMX Copenhagen A/S on October 17, 2012.

About daratumumab
Daratumumab is a human CD38 monoclonal antibody with broad-spectrum killing activity. Daratumumab is in clinical development for multiple myeloma (MM). Daratumumab targets the CD38 molecule which is highly expressed on the surface of multiple myeloma cells. Daratumumab could also have potential in other cancers on which CD38 is expressed, including diffuse large B-cell lymphoma, chronic lymphocytic leukemia, acute lymphoblastic leukemia, plasma cell leukemia, acute myeloid leukemia, follicular lymphoma and mantle cell lymphoma.

About Genmab A/S
Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated human antibody therapeutics for the treatment of cancer.  Founded in 1999, the company’s first marketed antibody, ofatumumab (Arzerra®), was approved to treat chronic lymphocytic leukemia in patients who are refractory to fludarabine and alemtuzumab after less than eight years in development.  Genmab’s validated and next generation antibody technologies are expected to provide a steady stream of future product candidates.  Partnering of innovative product candidates and technologies is a key focus of Genmab’s strategy and the company has alliances with top tier pharmaceutical and biotechnology companies.  For more information visit www.genmab.com.

Contact:          
Rachel Curtis Gravesen, Senior Vice President, Investor Relations & Communications
T: +45 33 44 77 20; M: +45 25 12 62 60; E: r.gravesen@genmab.com

This Company Announcement contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements in relation to actual results, unless required by law.

Genmab^®; the Y-shaped Genmab logo^®; HuMax^®; HuMax-CD20^®; DuoBody™ and UniBody^® are all trademarks of Genmab A/S. Arzerra^® is a trademark of GlaxoSmithKline.

Company Announcement no. 25
CVR no. 2102 3884

Genmab A/S
Bredgade 34E
1260 Copenhagen K
Denmark